Key result
Maternal low-dose aspirin during preeclampsia mitigates stroke severity and infarct size in adult offspring.
Why the study?
Preeclampsia is associated with increased long-term cardiovascular risk in adult offspring, but the impact of prophylactic maternal low-dose aspirin on offspring stroke outcomes remains unclear.
Does maternal low-dose aspirin treatment during experimental preeclampsia improve ischemic stroke outcomes in adult offspring?
Does maternal low-dose aspirin treatment during experimental preeclampsia improve ischemic stroke outcomes in adult offspring?
Maternal low-dose aspirin treatment during experimental preeclampsia mitigates worsened ischemic stroke severity and cerebrovascular inflammation in adult male offspring, suggesting protective effects of improving the intrauterine environment.
Maternal low-dose aspirin warrants no clinical extrapolation; hypothesis-generating for intergenerational stroke protection in experimental preeclampsia.
BACKGROUND: Preeclampsia, a serious hypertensive disorder of pregnancy, is associated with increased long-term risk of cardiovascular disease in adult offspring, particularly stroke. Although low-dose aspirin (LDA) is used prophylactically to prevent preeclampsia, its impact on offspring is unclear. This study investigated the effect of maternal LDA treatment during experimental preeclampsia (ePE) on adult first-generation (F1) offspring, including stroke outcome. METHODS: ePE was induced in pregnant Sprague-Dawley rats via a high-cholesterol diet starting on gestational day 7 and treated with LDA (1.5 mg/kg) or vehicle. Offspring were weaned and fed standard chow until transient middle cerebral artery occlusion at 12 to 18 weeks (3-hour ischemia and 1-hour reperfusion). Fetal and juvenile weights were taken at gestational day 20 and from weeks 10 to 13. Infarct and edema were quantified using 2,3,5-triphenyltetrazolium chloride staining. Multisite laser Doppler was used to measure cerebral hemodynamics, including cerebral blood flow autoregulation and collateral flow. Circulating proinflammatory and anti-inflammatory factors were measured via multiplex immunoassay. Maternal treatment with LDA was protective of male offspring (ePE+Asp-F1) that had reduced infarct and edema. Increased infarction in ePE-F1 males was associated with greater collateral perfusion deficit and elevated levels of TNF-α (tumor necrosis factor-alpha) and IL (interleukin)-1β that were prevented by maternal LDA treatment. There were no differences in infarct, edema, or perfusion deficit in female offspring. CONCLUSIONS: Prenatal exposure to ePE worsened stroke severity and inflammation in male but not female offspring, which was largely mitigated by maternal LDA treatment, potentially due to an improved intrauterine environment. These findings highlight a sex-specific impact of prenatal preeclampsia exposure on long-term cerebrovascular health and suggest that maternal LDA may confer long-lasting protection to the offspring in addition to the mother.
No takes yet. Share an insight, caveat, or question.
Hunt et al. (2026) studied Ischemic stroke and prenatal exposure to experimental preeclampsia. Maternal low-dose aspirin (LDA) vs. Vehicle (experimental preeclampsia without aspirin) and Normal pregnancy was evaluated on Infarct volume and percent edema following transient middle cerebral artery occlusion. Maternal low-dose aspirin treatment during experimental preeclampsia mitigated worsened stroke severity, infarct size, and inflammation in adult male offspring following ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: